AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 11 344 GBX 1.32%
Market Cap: 175.9B GBX
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one AZN stock under the Base Case scenario is hidden GBX. Compared to the current market price of 11 344 GBX, AstraZeneca PLC is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

4.2
P/S
P/S
Price to Sales
4.2
vs History
87
vs Industry
29
Median 3Y
4.5
Median 5Y
4.7
Industry
2.4
Forward
0
More Details
32.4
P/E
P/E
Price to Earnings
32.4
vs History
84
vs Industry
13
Median 3Y
35
Median 5Y
38
Industry
20.5
Forward
0.2
More Details
19.2
P/OCF
P/OCF
Price to OCF
19.2
vs History
88
vs Industry
23
Median 3Y
21.3
Median 5Y
22.9
Industry
15.4
More Details
29.6
P/FCFE
P/FCFE
Price to FCFE
29.6
vs History
55
vs Industry
16
Median 3Y
38.9
Median 5Y
30.3
Industry
22.6
More Details
5.6
P/B
P/B
Price to Book Value
5.6
vs History
55
vs Industry
12
Median 3Y
5.4
Median 5Y
5.8
Industry
2
More Details
45.5
EV/S
EV/S
Enterprise Value to Sales
45.5
vs History
66
vs Industry
5
Median 3Y
49.6
Median 5Y
48.8
Industry
2.5
Forward
0.4
More Details
55.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
55.3
vs History
69
vs Industry
3
Median 3Y
60.3
Median 5Y
60.3
Industry
4.9
More Details
126.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
126.9
vs History
95
vs Industry
2
Median 3Y
162.9
Median 5Y
158.6
Industry
12.6
Forward
1.2
More Details
193.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
193.8
vs History
95
vs Industry
2
Median 3Y
255
Median 5Y
272.7
Industry
15.6
Forward
1.3
More Details
207.2
EV/OCF
EV/OCF
Enterprise Value to OCF
207.2
vs History
71
vs Industry
2
Median 3Y
240.5
Median 5Y
243.3
Industry
13.9
More Details
337.8
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
337.8
vs History
66
vs Industry
1
Median 3Y
381.2
Median 5Y
407.8
Industry
17.7
More Details
34
EV/IC
EV/IC
Enterprise Value to IC
34
vs History
12
vs Industry
3
Median 3Y
32.1
Median 5Y
30
Industry
1.8
More Details

Multiples Across Competitors

AZN Competitors Multiples
AstraZeneca PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
AstraZeneca PLC
LSE:AZN
176.2B GBP 4.2 32.4 126.9 193.8
US
Eli Lilly and Co
NYSE:LLY
778.6B USD 17.3 73.5 42.7 47.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
392.6B USD 4.4 27.9 13.1 17.1
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.3 21 13.8 15.7
CH
Roche Holding AG
SIX:ROG
236.1B CHF 4 20.5 11.5 13.6
CH
Novartis AG
SIX:NOVN
199.5B CHF 4.4 18.9 11.4 14.7
US
Merck & Co Inc
NYSE:MRK
221.8B USD 3.5 13 8.8 10.4
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
141.7B USD 2.2 17.6 8.5 12.1
FR
Sanofi SA
PAR:SAN
129.3B EUR 2.9 22.4 9.7 14.2
P/E Multiple
Earnings Growth PEG
UK
AstraZeneca PLC
LSE:AZN
Average P/E: 27.5
32.4
36%
0.9
US
Eli Lilly and Co
NYSE:LLY
73.5
48%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
27.9
26%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
21
19%
1.1
CH
Roche Holding AG
SIX:ROG
20.5
16%
1.3
CH
Novartis AG
SIX:NOVN
18.9
16%
1.2
US
Merck & Co Inc
NYSE:MRK
13
17%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.6
29%
0.6
FR
Sanofi SA
PAR:SAN
22.4
29%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
AstraZeneca PLC
LSE:AZN
Average EV/EBITDA: 396.4
126.9
9%
14.1
US
Eli Lilly and Co
NYSE:LLY
42.7
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
13.1
7%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.8
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.5
8%
1.4
CH
Novartis AG
SIX:NOVN
11.4
5%
2.3
US
Merck & Co Inc
NYSE:MRK
8.8
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.5
3%
2.8
FR
Sanofi SA
PAR:SAN
9.7
7%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
AstraZeneca PLC
LSE:AZN
Average EV/EBIT: 1 701.1
193.8
21%
9.2
US
Eli Lilly and Co
NYSE:LLY
47.2
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
17.1
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
16%
1
CH
Roche Holding AG
SIX:ROG
13.6
9%
1.5
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10.4
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12.1
10%
1.2
FR
Sanofi SA
PAR:SAN
14.2
14%
1

See Also

Summary
AZN intrinsic value, competitors valuation, and company profile.
DCF Valuation
AZN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AZN stock valuation using valuation multiples.
Wall Street Estimates
AZN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AZN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 242,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.